Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuvisertib phase 1/2 study in intermediate- or high-risk myelofibrosis
jRCT2031210490Phase 2Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Aug 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of nuvisertib and mivavotinib in myelofibrosis (MF) (2 arms), sponsored by Sumitomo Pharma. Primary endpoints: Incidence of dose-limiting toxicities and Incidence of treatment-emergent adverse events. Started Aug 2022; status: recruiting.
02
Drugs
nuvisertibmivavotinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on jRCT2031210490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210490.